Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

Breast Cancer Research and Treatment

Volumn 124, Issue 3, 2010, Pages 745-753

  Launay Vacher, Vincent ^a   Gligorov, Joseph ^b   Le Tourneau, Christophe ^c   Janus, Nicolas ^a   Spano, Jean Philippe ^a   Ray Coquard, Isabelle ^d   Oudard, Stéphane ^e   Pourrat, Xavier ^f   Morere, Jean François ^g   Deray, Gilbert ^a   Beuzeboc, Philippe ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c INSTITUT CURIE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g AVICENNE HOSPITAL   (France)

Author keywords

Breast Cancer; Drug dosage adjustment; Kidney disease; Nephrotoxicity; Renal insufficiency

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; GOSERELIN; IRINOTECAN; LETROZOLE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PAMIDRONIC ACID; PIRARUBICIN; TAMOXIFEN; THIOTEPA; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINDESINE; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BREAST CANCER; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FRANCE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE NEOPLASMS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CREATININE; FEMALE; FRANCE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RENAL INSUFFICIENCY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 78649320899     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0131-1     Document Type: Article

References (28)

1. AJ Matas RL Simmons CM Kjellstrand TJ Buselmeier JS Najarian 1975 Increased incidence of malignancy during chronic renal failure Lancet 1 883 886 10.1016/S0140-6736(75)91684-0 1:STN:280:DyaE2M7jslSmtw%3D%3D 10.1016/S0140-6736(75)91684-0 47534
2. GA Sutherland J Glass R Gabriel 1977 Increased incidence of malignancy in chronic renal failure Nephron 18 182 184 10.1159/000130762 1:STN:280: DyaE2s7ntFGjsw%3D%3D 10.1159/000180813 859681
3. K Cengiz 2002 Increased incidence of neoplasia in chronic renal failure (20-year experience) Int Urol Nephrol 33 121 126 10.1023/A:1014489911153 10.1023/A:1014489911153 12090317
4. CA Jones GM McQuillan JW Kusek, et al. 1998 Serum creatinine levels in the US population: third national health and nutrition examination survey Am J Kidney Dis 32 992 999 10.1016/S0272-6386(98)70074-5 1:STN:280: DyaK1M%2Fnt1egtw%3D%3D 10.1016/S0272-6386(98)70074-5 9856515
5. V Launay-Vacher S Oudard N Janus J Gligorov X Pourrat O Rixe Renal Insufficiency and Cancer Medications (IRMA) Study Group, et al. 2007 Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study Cancer 110 6 1376 1384 10.1002/cncr.22904 1:CAS:528:DC%2BD2sXhtFCgtr%2FK 10.1002/cncr.22904 17634949 (Pubitemid 47435612)
6. National Kidney Foundation 2002 K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2(Suppl 1) S1 S266
7. AS Levey KU Eckardt Y Tsukamoto, et al. 2005 Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO) Kidney Int 67 2089 2100 10.1111/j.1523-1755.2005.00365.x 10.1111/j.1523-1755.2005.00365.x 15882252 (Pubitemid 41623371)
8. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M (2007) Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol Dec 7; [Epub ahead of print]
9. BP Coudert R Largillier L Arnould P Chollet M Campone D Coeffic, et al. 2007 Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial J Clin Oncol 25 19 2678 2684 10.1200/JCO.2006.09.9994 1:CAS:528:DC%2BD2sXosValt7c%3D 10.1200/JCO.2006.09.9994 17515572 (Pubitemid 47123173)
10. N Robert B Leyland-Jones L Asmar R Belt D Ilegbodu D Loesch, et al. 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 18 2786 2792 10.1200/JCO.2005.04.1764 1:CAS:528:DC%2BD28XntV2hu7g%3D 10.1200/JCO.2005.04.1764 16782917 (Pubitemid 46630577)
11. J Hurley P Doliny I Reis O Silva C Gomez-Fernandez P Velez, et al. 2006 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 21 3515 1:CAS:528:DC%2BD2sXlt1ers74%3D
12. Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium. San Antonio abstract 1
13. JJ Body 2006 Breast cancer: bisphosphonate therapy for metastatic bone disease Clin Cancer Res 12 6258s 6263s 10.1158/1078-0432.CCR-06-0840 1:CAS:528:DC%2BD28XhtFWhsbfL 10.1158/1078-0432.CCR-06-0840 17062710 (Pubitemid 44703799)
14. AD Tripathy I Diel JJ Body 2004 Ibandronate reduces skeletal morbidity in patients with breast cancer Semin Oncol 31 5(Suppl 10) 64 66 10.1053/j.seminoncol.2004.07.025 1:CAS:528:DC%2BD2cXhtVSlu7zL 10.1053/j.seminoncol.2004.07.025 (Pubitemid 39370113)
15. LS Rosen D Gordon M Kaminski A Howell A Belch J Mackey, et al. 2003 Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 8 1735 1744 10.1002/cncr.11701 1:CAS:528: DC%2BD3sXovVCrsLw%3D 10.1002/cncr.11701 14534891 (Pubitemid 37238631)
16. JT Chang L Green J Beitz 2003 Renal failure with the use of zoledronic acid N Engl J Med 349 17 1676 1679 10.1056/NEJM200310233491721 1:CAS:528:DC%2BD3sXosFakurw%3D 10.1056/NEJM200310233491721 14573746 (Pubitemid 37288581)
17. DW Cockcroft MH Gault 1976 Prediction of CrCl from serum creatinine Nephron 16 31 41 10.1159/000130554 1:STN:280:DyaE28%2FnsF2isw%3D%3D 10.1159/000180580 1244564
18. AS Levey T Greene JW Kusek 2000 A simplified equation to predict glomerular filtration rate from serum creatinine J Am Soc Nephrol 11 0828 abstract
19. Aronoff GR, Berns JS, Brier ME et al (1999) Drug prescribing in renal failure. Dosing guidelines for adults, 4th edn. American College of Physicians-American Society of Internal Medicine, USA
20. Launay-Vacher V, Karie S, Deray G (2005) GPR Anticancéreux. Guide de prescription des médicaments chez le patient insuffisant rénal, 3rd edn. Méditions International, France
21. S Lauro M Lalle D'Andrea A Vecchione L Frati 1994 Nephrotic syndrome and adjuvant treatment with tamoxifen for early breast cancer. Case report and review of the literature Anticancer Res 4 5B 171 172
22. A Merouani SA Davidson RW Schrier 1997 Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone Am J Nephrol 17 1 53 58 1:STN:280:DyaK2s3htV2htw%3D%3D 10.1159/000169072 9057954
23. E Nikolsky R Mehran Z Lasic, et al. 2005 Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions Kidney Int 67 706 713 10.1111/j.1523-1755.2005.67131.x 10.1111/j.1523-1755.2005.67131.x 15673320 (Pubitemid 40139864)
24. JJ Body R Coleman P Clezardin C Ripamonti R Rizzoli M Aapro International Society of Geriatric Oncology 2007 International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients Eur J Cancer 43 852 858 10.1016/j.ejca.2006.12.006 1:CAS:528:DC%2BD2sXisleitL8%3D 10.1016/j.ejca.2006.12.006 17258449 (Pubitemid 46366687)
25. S Lichtman H Wildiers V Launay-Vacher C Steer E Chatelut M Aapro 2007 International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency Eur J Cancer 43 14 34 10.1016/j.ejca.2006.11.004 10.1016/j.ejca.2006.11.004 17222747 (Pubitemid 46070218)
26. V Launay-Vacher E Chatelut S Lichtman H Wildiers C Steer M Aapro 2007 Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology (SIOG) clinical practice recommendations Ann Oncol 18 1314 1321 10.1093/annonc/mdm011 1:STN:280:DC%2BD2svntlWktA%3D%3D 10.1093/annonc/ mdm011 17631561 (Pubitemid 47305003)
27. M Aapro PA Abrahamsson JJ Body RE Coleman R Colomer L Costa, et al. 2008 Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 3 420 432 10.1093/annonc/mdm442 1:STN:280:DC%2BD1c7ksVSrug%3D%3D 10.1093/annonc/mdm442 17906299
28. JJ Body IJ Diel D Tripathy B Bergstrom 2006 Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results Eur J Cancer Care (Engl) 15 3 299 302 10.1111/j.1365-2354.2005.00641.x 1:STN:280:DC%2BD28vlvFSqsw%3D%3D 10.1111/j.1365-2354.2005.00641.x (Pubitemid 44050703)